Wagner AG » Molecular Microbiology (Virology)

University of Regensburg

Institute of Medical Microbiology and Hygiene

Molecular Microbiology (Virology)

Universität Regensburg

Prof. Dr. Ralf Wagner

Legal info


 

  • RESEARCH-BACKGROUND
  • RESEARCH-PROJECTS
    • Running Projects
      • HIVacToGC
      • NanoNeutVir
      • EHVA
      • HFVac3
      • MR-BioQuant
      • Virofight
      • TreatCancerV
      • DeeP-CMV
      • Inhibiting SARS-CoV-2 N-protein-mediated infectivity
      • TiKoCo
      • CoVaKo
      • THERIN
    • Past Projects
  • PUBLICATIONS
  • LECTURES
  • MEETINGS & EVENTS
  • NEWS & PRESS
  • TEAM
  • JOBS
  • NETWORKING
  • CONTACT
WHO

Running Projects

Project descriptions:

  • HIVacToGC: HIV Vaccine Targeting via DNA Origami Nanoparticles to lymph nodes to promote Germinal Center formation

  • NanoNeutVir: Development of nanotechnology-based novel rapid test to detect SARS-CoV-2 immunity

  • EHVA: European HIV Vaccine Alliance

  • HFVac3: Clinical trial of a DIOS Trivalent Haemorrhagic Fever Vaccine

  • MR-BioQuant: Ultrasensitive Magnetresonanz für die in vitro Biomarkerquantifizierung in Diagnostik und Therapie

  • Virofight: European Consortium for the Development of Novel Therapies against Viruses such as SARS-CoV-2, HIV, Influenza or Heaptitis

  • TreatCancerV: Treating cancer by targeting endogenous retroviral fossils within the human genome

  • Deep-CMV: Diagnostic, therapy and prevention before cytomegaloviral infection

  • Inhibiting SARS-CoV-2 N-protein-mediated infectivity

  • TiKoCo: Tirschenreuth-Kohorte-Covid-19 study

  • CoVaKo: Course of COVID-19 in vaccinated and non-vaccinated people

     

     

  • THERIN: A therapeutic vaccine to eradicate pre-malignant HPV16 and HPV18 infection and prevent cancer

  • Hector: Influence of HIV's glycan shield on the function and longevity of vaccine-induced immune responses